nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—Staphylococcal infection—Vandetanib—thyroid cancer	0.0409	0.0738	CcSEcCtD
Pimecrolimus—Other conjunctivitis—Epirubicin—thyroid cancer	0.037	0.0667	CcSEcCtD
Pimecrolimus—Other conjunctivitis—Doxorubicin—thyroid cancer	0.0342	0.0617	CcSEcCtD
Pimecrolimus—Squamous cell carcinoma—Sorafenib—thyroid cancer	0.0211	0.038	CcSEcCtD
Pimecrolimus—Skin cancer—Sorafenib—thyroid cancer	0.0154	0.0279	CcSEcCtD
Pimecrolimus—Furuncle—Vandetanib—thyroid cancer	0.0145	0.0261	CcSEcCtD
Pimecrolimus—Folliculitis—Vandetanib—thyroid cancer	0.0113	0.0204	CcSEcCtD
Pimecrolimus—MTOR—neck—thyroid cancer	0.0106	0.212	CbGeAlD
Pimecrolimus—FKBP1A—neck—thyroid cancer	0.00952	0.191	CbGeAlD
Pimecrolimus—Acne—Vandetanib—thyroid cancer	0.00844	0.0152	CcSEcCtD
Pimecrolimus—Folliculitis—Sorafenib—thyroid cancer	0.00762	0.0137	CcSEcCtD
Pimecrolimus—Oropharyngeal discomfort—Sorafenib—thyroid cancer	0.00658	0.0119	CcSEcCtD
Pimecrolimus—Leukaemia—Epirubicin—thyroid cancer	0.00657	0.0118	CcSEcCtD
Pimecrolimus—Leukaemia—Doxorubicin—thyroid cancer	0.00608	0.011	CcSEcCtD
Pimecrolimus—Rhinorrhoea—Sorafenib—thyroid cancer	0.00591	0.0107	CcSEcCtD
Pimecrolimus—Gastroenteritis—Vandetanib—thyroid cancer	0.00581	0.0105	CcSEcCtD
Pimecrolimus—FKBP1A—trachea—thyroid cancer	0.00573	0.115	CbGeAlD
Pimecrolimus—Neoplasm malignant—Sorafenib—thyroid cancer	0.00561	0.0101	CcSEcCtD
Pimecrolimus—Bone disorder—Sorafenib—thyroid cancer	0.0053	0.00956	CcSEcCtD
Pimecrolimus—MTOR—thyroid gland—thyroid cancer	0.00504	0.101	CbGeAlD
Pimecrolimus—Sensitisation—Epirubicin—thyroid cancer	0.00496	0.00893	CcSEcCtD
Pimecrolimus—Influenza like illness—Sorafenib—thyroid cancer	0.00465	0.00839	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Vandetanib—thyroid cancer	0.00461	0.00831	CcSEcCtD
Pimecrolimus—Sensitisation—Doxorubicin—thyroid cancer	0.00458	0.00827	CcSEcCtD
Pimecrolimus—Skin exfoliation—Sorafenib—thyroid cancer	0.00457	0.00824	CcSEcCtD
Pimecrolimus—FKBP1A—thyroid gland—thyroid cancer	0.00453	0.0909	CbGeAlD
Pimecrolimus—MTOR—head—thyroid cancer	0.00447	0.0897	CbGeAlD
Pimecrolimus—Influenza—Vandetanib—thyroid cancer	0.00445	0.00803	CcSEcCtD
Pimecrolimus—Bronchitis—Vandetanib—thyroid cancer	0.00428	0.00772	CcSEcCtD
Pimecrolimus—Leukoderma—Epirubicin—thyroid cancer	0.00416	0.00751	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00414	0.00746	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00407	0.00733	CcSEcCtD
Pimecrolimus—FKBP1A—head—thyroid cancer	0.00402	0.0806	CbGeAlD
Pimecrolimus—Pneumonia—Vandetanib—thyroid cancer	0.00399	0.0072	CcSEcCtD
Pimecrolimus—Infestation NOS—Vandetanib—thyroid cancer	0.00397	0.00716	CcSEcCtD
Pimecrolimus—Infestation—Vandetanib—thyroid cancer	0.00397	0.00716	CcSEcCtD
Pimecrolimus—Conjunctivitis—Vandetanib—thyroid cancer	0.00386	0.00696	CcSEcCtD
Pimecrolimus—Leukoderma—Doxorubicin—thyroid cancer	0.00385	0.00695	CcSEcCtD
Pimecrolimus—Epistaxis—Vandetanib—thyroid cancer	0.00375	0.00675	CcSEcCtD
Pimecrolimus—Sinusitis—Vandetanib—thyroid cancer	0.00373	0.00672	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.00368	0.00664	CcSEcCtD
Pimecrolimus—Furuncle—Epirubicin—thyroid cancer	0.00361	0.00651	CcSEcCtD
Pimecrolimus—Furuncle—Doxorubicin—thyroid cancer	0.00334	0.00602	CcSEcCtD
Pimecrolimus—Eye disorder—Vandetanib—thyroid cancer	0.00333	0.00601	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Vandetanib—thyroid cancer	0.00321	0.00579	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Sorafenib—thyroid cancer	0.00317	0.00572	CcSEcCtD
Pimecrolimus—Breast disorder—Sorafenib—thyroid cancer	0.00314	0.00566	CcSEcCtD
Pimecrolimus—MTOR—lymph node—thyroid cancer	0.00313	0.0628	CbGeAlD
Pimecrolimus—Nasopharyngitis—Sorafenib—thyroid cancer	0.00311	0.0056	CcSEcCtD
Pimecrolimus—Malnutrition—Vandetanib—thyroid cancer	0.0031	0.0056	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Epirubicin—thyroid cancer	0.00298	0.00536	CcSEcCtD
Pimecrolimus—FKBP1A—lymph node—thyroid cancer	0.00282	0.0565	CbGeAlD
Pimecrolimus—Folliculitis—Epirubicin—thyroid cancer	0.00282	0.00508	CcSEcCtD
Pimecrolimus—Skin hyperpigmentation—Doxorubicin—thyroid cancer	0.00275	0.00496	CcSEcCtD
Pimecrolimus—Cough—Vandetanib—thyroid cancer	0.00271	0.00488	CcSEcCtD
Pimecrolimus—Pneumonia—Sorafenib—thyroid cancer	0.00269	0.00486	CcSEcCtD
Pimecrolimus—Infestation NOS—Sorafenib—thyroid cancer	0.00268	0.00483	CcSEcCtD
Pimecrolimus—Infestation—Sorafenib—thyroid cancer	0.00268	0.00483	CcSEcCtD
Pimecrolimus—Arthralgia—Vandetanib—thyroid cancer	0.00264	0.00476	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00262	0.00473	CcSEcCtD
Pimecrolimus—Folliculitis—Doxorubicin—thyroid cancer	0.00261	0.0047	CcSEcCtD
Pimecrolimus—Oedema—Vandetanib—thyroid cancer	0.00253	0.00457	CcSEcCtD
Pimecrolimus—Epistaxis—Sorafenib—thyroid cancer	0.00253	0.00456	CcSEcCtD
Pimecrolimus—Infection—Vandetanib—thyroid cancer	0.00252	0.00454	CcSEcCtD
Pimecrolimus—Nervous system disorder—Vandetanib—thyroid cancer	0.00248	0.00448	CcSEcCtD
Pimecrolimus—Skin disorder—Vandetanib—thyroid cancer	0.00246	0.00444	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00231	0.00416	CcSEcCtD
Pimecrolimus—Paraesthesia—Vandetanib—thyroid cancer	0.00227	0.0041	CcSEcCtD
Pimecrolimus—Otitis media—Epirubicin—thyroid cancer	0.00227	0.0041	CcSEcCtD
Pimecrolimus—Dyspnoea—Vandetanib—thyroid cancer	0.00226	0.00407	CcSEcCtD
Pimecrolimus—Flushing—Sorafenib—thyroid cancer	0.00223	0.00402	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00219	0.00394	CcSEcCtD
Pimecrolimus—Immune system disorder—Sorafenib—thyroid cancer	0.00217	0.00392	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Sorafenib—thyroid cancer	0.00217	0.00391	CcSEcCtD
Pimecrolimus—Constipation—Vandetanib—thyroid cancer	0.00217	0.00391	CcSEcCtD
Pimecrolimus—Pain—Vandetanib—thyroid cancer	0.00217	0.00391	CcSEcCtD
Pimecrolimus—Otitis media—Doxorubicin—thyroid cancer	0.0021	0.00379	CcSEcCtD
Pimecrolimus—Malnutrition—Sorafenib—thyroid cancer	0.00209	0.00377	CcSEcCtD
Pimecrolimus—Erythema—Sorafenib—thyroid cancer	0.00209	0.00377	CcSEcCtD
Pimecrolimus—Neoplasm malignant—Epirubicin—thyroid cancer	0.00207	0.00374	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00207	0.00373	CcSEcCtD
Pimecrolimus—Abdominal pain—Vandetanib—thyroid cancer	0.002	0.00361	CcSEcCtD
Pimecrolimus—Body temperature increased—Vandetanib—thyroid cancer	0.002	0.00361	CcSEcCtD
Pimecrolimus—Viral infection—Epirubicin—thyroid cancer	0.00196	0.00353	CcSEcCtD
Pimecrolimus—Skin discolouration—Epirubicin—thyroid cancer	0.00196	0.00353	CcSEcCtD
Pimecrolimus—Bone disorder—Epirubicin—thyroid cancer	0.00196	0.00353	CcSEcCtD
Pimecrolimus—Herpes simplex—Epirubicin—thyroid cancer	0.00192	0.00346	CcSEcCtD
Pimecrolimus—Neoplasm malignant—Doxorubicin—thyroid cancer	0.00192	0.00346	CcSEcCtD
Pimecrolimus—Angioedema—Sorafenib—thyroid cancer	0.00191	0.00345	CcSEcCtD
Pimecrolimus—Cough—Sorafenib—thyroid cancer	0.00183	0.00329	CcSEcCtD
Pimecrolimus—Viral infection—Doxorubicin—thyroid cancer	0.00181	0.00327	CcSEcCtD
Pimecrolimus—Skin discolouration—Doxorubicin—thyroid cancer	0.00181	0.00327	CcSEcCtD
Pimecrolimus—Bone disorder—Doxorubicin—thyroid cancer	0.00181	0.00327	CcSEcCtD
Pimecrolimus—Pruritus—Vandetanib—thyroid cancer	0.00179	0.00323	CcSEcCtD
Pimecrolimus—Arthralgia—Sorafenib—thyroid cancer	0.00178	0.00321	CcSEcCtD
Pimecrolimus—Herpes simplex—Doxorubicin—thyroid cancer	0.00178	0.0032	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00177	0.00319	CcSEcCtD
Pimecrolimus—Diarrhoea—Vandetanib—thyroid cancer	0.00173	0.00312	CcSEcCtD
Pimecrolimus—Influenza like illness—Epirubicin—thyroid cancer	0.00172	0.0031	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Sorafenib—thyroid cancer	0.00171	0.00308	CcSEcCtD
Pimecrolimus—Infection—Sorafenib—thyroid cancer	0.0017	0.00306	CcSEcCtD
Pimecrolimus—Skin exfoliation—Epirubicin—thyroid cancer	0.00169	0.00305	CcSEcCtD
Pimecrolimus—Nervous system disorder—Sorafenib—thyroid cancer	0.00168	0.00302	CcSEcCtD
Pimecrolimus—Skin disorder—Sorafenib—thyroid cancer	0.00166	0.00299	CcSEcCtD
Pimecrolimus—Vomiting—Vandetanib—thyroid cancer	0.00161	0.0029	CcSEcCtD
Pimecrolimus—Rash—Vandetanib—thyroid cancer	0.0016	0.00288	CcSEcCtD
Pimecrolimus—Dermatitis—Vandetanib—thyroid cancer	0.0016	0.00288	CcSEcCtD
Pimecrolimus—Influenza like illness—Doxorubicin—thyroid cancer	0.00159	0.00287	CcSEcCtD
Pimecrolimus—Headache—Vandetanib—thyroid cancer	0.00159	0.00286	CcSEcCtD
Pimecrolimus—Skin exfoliation—Doxorubicin—thyroid cancer	0.00156	0.00282	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00156	0.00281	CcSEcCtD
Pimecrolimus—Dyspnoea—Sorafenib—thyroid cancer	0.00152	0.00275	CcSEcCtD
Pimecrolimus—Nausea—Vandetanib—thyroid cancer	0.0015	0.00271	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00148	0.00266	CcSEcCtD
Pimecrolimus—Pain—Sorafenib—thyroid cancer	0.00146	0.00263	CcSEcCtD
Pimecrolimus—Constipation—Sorafenib—thyroid cancer	0.00146	0.00263	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Sorafenib—thyroid cancer	0.0014	0.00252	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00136	0.00245	CcSEcCtD
Pimecrolimus—Urticaria—Sorafenib—thyroid cancer	0.00136	0.00245	CcSEcCtD
Pimecrolimus—Abdominal pain—Sorafenib—thyroid cancer	0.00135	0.00244	CcSEcCtD
Pimecrolimus—Body temperature increased—Sorafenib—thyroid cancer	0.00135	0.00244	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00126	0.00227	CcSEcCtD
Pimecrolimus—Hypersensitivity—Sorafenib—thyroid cancer	0.00126	0.00227	CcSEcCtD
Pimecrolimus—Face oedema—Epirubicin—thyroid cancer	0.00124	0.00224	CcSEcCtD
Pimecrolimus—Pruritus—Sorafenib—thyroid cancer	0.00121	0.00218	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Epirubicin—thyroid cancer	0.00117	0.00212	CcSEcCtD
Pimecrolimus—Diarrhoea—Sorafenib—thyroid cancer	0.00117	0.00211	CcSEcCtD
Pimecrolimus—Breast disorder—Epirubicin—thyroid cancer	0.00116	0.00209	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Epirubicin—thyroid cancer	0.00115	0.00207	CcSEcCtD
Pimecrolimus—Face oedema—Doxorubicin—thyroid cancer	0.00115	0.00207	CcSEcCtD
Pimecrolimus—Influenza—Epirubicin—thyroid cancer	0.00111	0.002	CcSEcCtD
Pimecrolimus—Asthma—Epirubicin—thyroid cancer	0.00111	0.002	CcSEcCtD
Pimecrolimus—Vomiting—Sorafenib—thyroid cancer	0.00109	0.00196	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00109	0.00196	CcSEcCtD
Pimecrolimus—Rash—Sorafenib—thyroid cancer	0.00108	0.00194	CcSEcCtD
Pimecrolimus—Dermatitis—Sorafenib—thyroid cancer	0.00108	0.00194	CcSEcCtD
Pimecrolimus—Breast disorder—Doxorubicin—thyroid cancer	0.00107	0.00194	CcSEcCtD
Pimecrolimus—Headache—Sorafenib—thyroid cancer	0.00107	0.00193	CcSEcCtD
Pimecrolimus—Bronchitis—Epirubicin—thyroid cancer	0.00107	0.00193	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00106	0.00192	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00103	0.00186	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—thyroid cancer	0.00103	0.00185	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—thyroid cancer	0.00103	0.00185	CcSEcCtD
Pimecrolimus—Nausea—Sorafenib—thyroid cancer	0.00101	0.00183	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00101	0.00183	CcSEcCtD
Pimecrolimus—Pneumonia—Epirubicin—thyroid cancer	0.000996	0.0018	CcSEcCtD
Pimecrolimus—Infestation—Epirubicin—thyroid cancer	0.00099	0.00179	CcSEcCtD
Pimecrolimus—Infestation NOS—Epirubicin—thyroid cancer	0.00099	0.00179	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—thyroid cancer	0.000988	0.00178	CcSEcCtD
Pimecrolimus—Conjunctivitis—Epirubicin—thyroid cancer	0.000962	0.00174	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000955	0.00172	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000938	0.00169	CcSEcCtD
Pimecrolimus—Epistaxis—Epirubicin—thyroid cancer	0.000934	0.00168	CcSEcCtD
Pimecrolimus—Sinusitis—Epirubicin—thyroid cancer	0.000929	0.00167	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—thyroid cancer	0.000921	0.00166	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—thyroid cancer	0.000916	0.00165	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—thyroid cancer	0.000916	0.00165	CcSEcCtD
Pimecrolimus—Rhinitis—Epirubicin—thyroid cancer	0.000891	0.00161	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—thyroid cancer	0.00089	0.00161	CcSEcCtD
Pimecrolimus—Pharyngitis—Epirubicin—thyroid cancer	0.000882	0.00159	CcSEcCtD
Pimecrolimus—Epistaxis—Doxorubicin—thyroid cancer	0.000864	0.00156	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—thyroid cancer	0.000859	0.00155	CcSEcCtD
Pimecrolimus—Eye disorder—Epirubicin—thyroid cancer	0.000831	0.0015	CcSEcCtD
Pimecrolimus—Flushing—Epirubicin—thyroid cancer	0.000825	0.00149	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—thyroid cancer	0.000824	0.00149	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—thyroid cancer	0.000816	0.00147	CcSEcCtD
Pimecrolimus—Immune system disorder—Epirubicin—thyroid cancer	0.000803	0.00145	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Epirubicin—thyroid cancer	0.000801	0.00144	CcSEcCtD
Pimecrolimus—Erythema—Epirubicin—thyroid cancer	0.000774	0.00139	CcSEcCtD
Pimecrolimus—Malnutrition—Epirubicin—thyroid cancer	0.000774	0.00139	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—thyroid cancer	0.000768	0.00139	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—thyroid cancer	0.000763	0.00138	CcSEcCtD
Pimecrolimus—Back pain—Epirubicin—thyroid cancer	0.000748	0.00135	CcSEcCtD
Pimecrolimus—Immune system disorder—Doxorubicin—thyroid cancer	0.000743	0.00134	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000741	0.00134	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—thyroid cancer	0.000716	0.00129	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—thyroid cancer	0.000716	0.00129	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—thyroid cancer	0.000692	0.00125	CcSEcCtD
Pimecrolimus—Cough—Epirubicin—thyroid cancer	0.000675	0.00122	CcSEcCtD
Pimecrolimus—Arthralgia—Epirubicin—thyroid cancer	0.000659	0.00119	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000654	0.00118	CcSEcCtD
Pimecrolimus—Oedema—Epirubicin—thyroid cancer	0.000631	0.00114	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Epirubicin—thyroid cancer	0.000631	0.00114	CcSEcCtD
Pimecrolimus—Infection—Epirubicin—thyroid cancer	0.000627	0.00113	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—thyroid cancer	0.000625	0.00113	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000623	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—AKT1—thyroid cancer	0.000623	0.00158	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MEN1—thyroid cancer	0.000622	0.00157	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Epirubicin—thyroid cancer	0.000619	0.00112	CcSEcCtD
Pimecrolimus—MTOR—mTOR signaling pathway—AKT1—thyroid cancer	0.000616	0.00156	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—AKT1—thyroid cancer	0.000616	0.00156	CbGpPWpGaD
Pimecrolimus—Skin disorder—Epirubicin—thyroid cancer	0.000613	0.00111	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—NRAS—thyroid cancer	0.000611	0.00155	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BRAF—thyroid cancer	0.00061	0.00154	CbGpPWpGaD
Pimecrolimus—Arthralgia—Doxorubicin—thyroid cancer	0.000609	0.0011	CcSEcCtD
Pimecrolimus—MTOR—Signaling by Insulin receptor—NRAS—thyroid cancer	0.000607	0.00153	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000605	0.00109	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—HIF1A—thyroid cancer	0.000604	0.00153	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—AKT1—thyroid cancer	0.000601	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—AKT1—thyroid cancer	0.000601	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—thyroid cancer	0.000598	0.00151	CbGpPWpGaD
Pimecrolimus—MTOR—SREBP signalling—AKT1—thyroid cancer	0.000594	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—AKT1—thyroid cancer	0.000594	0.0015	CbGpPWpGaD
Pimecrolimus—Oedema—Doxorubicin—thyroid cancer	0.000584	0.00105	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000584	0.00105	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—PTEN—thyroid cancer	0.000582	0.00147	CbGpPWpGaD
Pimecrolimus—Infection—Doxorubicin—thyroid cancer	0.00058	0.00105	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000575	0.00104	CcSEcCtD
Pimecrolimus—Nervous system disorder—Doxorubicin—thyroid cancer	0.000573	0.00103	CcSEcCtD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000572	0.00145	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000571	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—HRAS—thyroid cancer	0.000569	0.00144	CbGpPWpGaD
Pimecrolimus—Skin disorder—Doxorubicin—thyroid cancer	0.000567	0.00102	CcSEcCtD
Pimecrolimus—Paraesthesia—Epirubicin—thyroid cancer	0.000567	0.00102	CcSEcCtD
Pimecrolimus—MTOR—ErbB1 downstream signaling—KRAS—thyroid cancer	0.000566	0.00143	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Epirubicin—thyroid cancer	0.000563	0.00102	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—CALCB—thyroid cancer	0.000563	0.00142	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—thyroid cancer	0.000557	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—PTEN—thyroid cancer	0.000557	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—AKT1—thyroid cancer	0.000556	0.00141	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000554	0.0014	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—HRAS—thyroid cancer	0.000554	0.0014	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000551	0.00139	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—thyroid cancer	0.000549	0.00139	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—PTEN—thyroid cancer	0.000548	0.00139	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000545	0.000983	CcSEcCtD
Pimecrolimus—Pain—Epirubicin—thyroid cancer	0.00054	0.000974	CcSEcCtD
Pimecrolimus—Constipation—Epirubicin—thyroid cancer	0.00054	0.000974	CcSEcCtD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—HRAS—thyroid cancer	0.000534	0.00135	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—HRAS—thyroid cancer	0.000534	0.00135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TRIM33—thyroid cancer	0.000534	0.00135	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000532	0.00096	CcSEcCtD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—thyroid cancer	0.000528	0.00133	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—KRAS—thyroid cancer	0.000526	0.00133	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—PTEN—thyroid cancer	0.000526	0.00133	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Doxorubicin—thyroid cancer	0.000525	0.000946	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—PTEN—thyroid cancer	0.000523	0.00132	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—KRAS—thyroid cancer	0.000522	0.00132	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Doxorubicin—thyroid cancer	0.000521	0.000939	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR—PTEN—thyroid cancer	0.000521	0.00132	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—PTEN—thyroid cancer	0.000521	0.00132	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—NRAS—thyroid cancer	0.000519	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—PTEN—thyroid cancer	0.000518	0.00131	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000516	0.000931	CcSEcCtD
Pimecrolimus—MTOR—DAP12 signaling—PTEN—thyroid cancer	0.000516	0.0013	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TCF7L1—thyroid cancer	0.000508	0.00129	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PTEN—thyroid cancer	0.000508	0.00129	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—AKT1—thyroid cancer	0.000508	0.00128	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thyroid cancer	0.000508	0.00128	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000504	0.000909	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—thyroid cancer	0.000503	0.00127	CbGpPWpGaD
Pimecrolimus—Urticaria—Epirubicin—thyroid cancer	0.000502	0.000904	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—thyroid cancer	0.0005	0.000901	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—thyroid cancer	0.0005	0.000901	CcSEcCtD
Pimecrolimus—Abdominal pain—Epirubicin—thyroid cancer	0.000499	0.0009	CcSEcCtD
Pimecrolimus—Body temperature increased—Epirubicin—thyroid cancer	0.000499	0.0009	CcSEcCtD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thyroid cancer	0.000498	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—NRAS—thyroid cancer	0.000497	0.00126	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CALCA—thyroid cancer	0.000495	0.00125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—NRAS—thyroid cancer	0.000489	0.00124	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—PTEN—thyroid cancer	0.000485	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PTEN—thyroid cancer	0.000485	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—PTEN—thyroid cancer	0.000485	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—HRAS—thyroid cancer	0.000481	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—thyroid cancer	0.000481	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—PTEN—thyroid cancer	0.000481	0.00122	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000478	0.000861	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—PTEN—thyroid cancer	0.000477	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—PTEN—thyroid cancer	0.000474	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—thyroid cancer	0.000474	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—BRAF—thyroid cancer	0.000469	0.00119	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CDK1—thyroid cancer	0.000469	0.00119	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000468	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—NRAS—thyroid cancer	0.000467	0.00118	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Epirubicin—thyroid cancer	0.000465	0.000839	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR—NRAS—thyroid cancer	0.000465	0.00117	CbGpPWpGaD
Pimecrolimus—Urticaria—Doxorubicin—thyroid cancer	0.000464	0.000837	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—TSHR—thyroid cancer	0.000463	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—NRAS—thyroid cancer	0.000462	0.00117	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Doxorubicin—thyroid cancer	0.000462	0.000833	CcSEcCtD
Pimecrolimus—Abdominal pain—Doxorubicin—thyroid cancer	0.000462	0.000833	CcSEcCtD
Pimecrolimus—MTOR—DAP12 signaling—NRAS—thyroid cancer	0.00046	0.00116	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000456	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—thyroid cancer	0.000453	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IFNA2—thyroid cancer	0.000451	0.00114	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—PTEN—thyroid cancer	0.000449	0.00114	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—AKT1—thyroid cancer	0.000449	0.00113	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDK1—thyroid cancer	0.000448	0.00113	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—HRAS—thyroid cancer	0.000447	0.00113	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—KRAS—thyroid cancer	0.000447	0.00113	CbGpPWpGaD
Pimecrolimus—Pruritus—Epirubicin—thyroid cancer	0.000447	0.000805	CcSEcCtD
Pimecrolimus—MTOR—Signaling by Insulin receptor—HRAS—thyroid cancer	0.000444	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—AKT1—thyroid cancer	0.000438	0.00111	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MEN1—thyroid cancer	0.000436	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—AKT1—thyroid cancer	0.000435	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—thyroid cancer	0.000433	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—NRAS—thyroid cancer	0.000433	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—NRAS—thyroid cancer	0.000433	0.00109	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Epirubicin—thyroid cancer	0.000432	0.000779	CcSEcCtD
Pimecrolimus—Hypersensitivity—Doxorubicin—thyroid cancer	0.00043	0.000776	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—thyroid cancer	0.00043	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—NRAS—thyroid cancer	0.000429	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—KRAS—thyroid cancer	0.000428	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—NRAS—thyroid cancer	0.000425	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—AKT1—thyroid cancer	0.000425	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thyroid cancer	0.000425	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—NRAS—thyroid cancer	0.000423	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000423	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—KRAS—thyroid cancer	0.000421	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—thyroid cancer	0.000418	0.00106	CbGpPWpGaD
Pimecrolimus—Pruritus—Doxorubicin—thyroid cancer	0.000413	0.000745	CcSEcCtD
Pimecrolimus—MTOR—Immune System—TPR—thyroid cancer	0.000403	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—KRAS—thyroid cancer	0.000402	0.00102	CbGpPWpGaD
Pimecrolimus—Vomiting—Epirubicin—thyroid cancer	0.000401	0.000724	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—NRAS—thyroid cancer	0.000401	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—thyroid cancer	0.0004	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—KRAS—thyroid cancer	0.0004	0.00101	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Doxorubicin—thyroid cancer	0.0004	0.000721	CcSEcCtD
Pimecrolimus—MTOR—Immune System—LGALS3—thyroid cancer	0.0004	0.00101	CbGpPWpGaD
Pimecrolimus—Rash—Epirubicin—thyroid cancer	0.000398	0.000718	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—KRAS—thyroid cancer	0.000398	0.00101	CbGpPWpGaD
Pimecrolimus—Dermatitis—Epirubicin—thyroid cancer	0.000398	0.000717	CcSEcCtD
Pimecrolimus—MTOR—Immune System—PRKAR1A—thyroid cancer	0.000396	0.001	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—KRAS—thyroid cancer	0.000396	0.001	CbGpPWpGaD
Pimecrolimus—Headache—Epirubicin—thyroid cancer	0.000396	0.000713	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—AKT1—thyroid cancer	0.000395	0.000998	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTCH1—thyroid cancer	0.000394	0.000996	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—thyroid cancer	0.00039	0.000987	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—thyroid cancer	0.000383	0.000969	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—HRAS—thyroid cancer	0.00038	0.00096	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRG1—thyroid cancer	0.000376	0.000951	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000376	0.000951	CbGpPWpGaD
Pimecrolimus—Nausea—Epirubicin—thyroid cancer	0.000375	0.000676	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—HRAS—thyroid cancer	0.000373	0.000944	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—KRAS—thyroid cancer	0.000373	0.000942	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—KRAS—thyroid cancer	0.000373	0.000942	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—thyroid cancer	0.000373	0.000942	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TPR—thyroid cancer	0.000372	0.000941	CbGpPWpGaD
Pimecrolimus—Vomiting—Doxorubicin—thyroid cancer	0.000371	0.00067	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—KRAS—thyroid cancer	0.000369	0.000933	CbGpPWpGaD
Pimecrolimus—Rash—Doxorubicin—thyroid cancer	0.000368	0.000664	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—thyroid cancer	0.000368	0.000664	CcSEcCtD
Pimecrolimus—MTOR—Disease—PRKAR1A—thyroid cancer	0.000366	0.000925	CbGpPWpGaD
Pimecrolimus—Headache—Doxorubicin—thyroid cancer	0.000366	0.00066	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—KRAS—thyroid cancer	0.000366	0.000925	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—KRAS—thyroid cancer	0.000364	0.000921	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—thyroid cancer	0.000363	0.000919	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRG1—thyroid cancer	0.000361	0.000914	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SST—thyroid cancer	0.00036	0.000911	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRG1—thyroid cancer	0.00036	0.00091	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—HRAS—thyroid cancer	0.000358	0.000904	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TCF7L1—thyroid cancer	0.000356	0.0009	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MEN1—thyroid cancer	0.00035	0.000884	CbGpPWpGaD
Pimecrolimus—Nausea—Doxorubicin—thyroid cancer	0.000347	0.000626	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—CALCA—thyroid cancer	0.000347	0.000877	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—KRAS—thyroid cancer	0.000345	0.000872	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—HRAS—thyroid cancer	0.000343	0.000868	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—HRAS—thyroid cancer	0.000342	0.000864	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—HRAS—thyroid cancer	0.00034	0.000859	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	0.00034	0.000859	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—HRAS—thyroid cancer	0.000338	0.000855	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—HRAS—thyroid cancer	0.000337	0.000851	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—AKT1—thyroid cancer	0.000335	0.000848	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	0.000332	0.000839	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PTEN—thyroid cancer	0.00033	0.000836	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	0.00033	0.000834	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—AKT1—thyroid cancer	0.00033	0.000834	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TERT—thyroid cancer	0.000323	0.000817	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—thyroid cancer	0.000321	0.000811	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000317	0.000803	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	0.000317	0.000801	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—HRAS—thyroid cancer	0.000317	0.000801	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HRAS—thyroid cancer	0.000317	0.000801	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—AKT1—thyroid cancer	0.000316	0.000798	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDK1—thyroid cancer	0.000314	0.000794	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—HRAS—thyroid cancer	0.000314	0.000793	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—thyroid cancer	0.000311	0.000786	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—HRAS—thyroid cancer	0.00031	0.000783	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HIF1A—thyroid cancer	0.000309	0.000781	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000304	0.000769	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—AKT1—thyroid cancer	0.000303	0.000766	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—AKT1—thyroid cancer	0.000302	0.000763	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—AKT1—thyroid cancer	0.0003	0.000759	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	0.0003	0.000759	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—AKT1—thyroid cancer	0.000299	0.000755	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—AKT1—thyroid cancer	0.000297	0.000751	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NRAS—thyroid cancer	0.000295	0.000745	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—HRAS—thyroid cancer	0.000293	0.000741	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	0.000293	0.000741	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	0.00028	0.000709	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—thyroid cancer	0.00028	0.000707	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—thyroid cancer	0.00028	0.000707	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	0.00028	0.000707	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CALCA—thyroid cancer	0.000279	0.000704	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—thyroid cancer	0.000277	0.000701	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—thyroid cancer	0.000275	0.000694	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—thyroid cancer	0.000273	0.000691	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDK1—thyroid cancer	0.000273	0.00069	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNA2—thyroid cancer	0.000263	0.000664	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TSHR—thyroid cancer	0.000261	0.000659	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT1—thyroid cancer	0.000259	0.000654	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000256	0.000648	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—BRAF—thyroid cancer	0.000256	0.000647	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KRAS—thyroid cancer	0.000254	0.000642	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDK1—thyroid cancer	0.000252	0.000637	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRG1—thyroid cancer	0.000252	0.000637	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	0.000248	0.000626	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MEN1—thyroid cancer	0.000245	0.000619	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—thyroid cancer	0.00024	0.000608	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TERT—thyroid cancer	0.000226	0.000572	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000223	0.000565	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTCH1—thyroid cancer	0.000222	0.00056	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRG1—thyroid cancer	0.000219	0.000554	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HIF1A—thyroid cancer	0.000216	0.000547	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—HRAS—thyroid cancer	0.000216	0.000545	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—thyroid cancer	0.000207	0.000523	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SST—thyroid cancer	0.000203	0.000512	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRG1—thyroid cancer	0.000202	0.000512	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CALCA—thyroid cancer	0.000195	0.000493	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—thyroid cancer	0.00019	0.000482	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.00019	0.00048	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTEN—thyroid cancer	0.000188	0.000477	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TERT—thyroid cancer	0.000182	0.000459	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTEN—thyroid cancer	0.000181	0.000458	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTEN—thyroid cancer	0.00018	0.000456	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—BRAF—thyroid cancer	0.000179	0.000453	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CHST14—thyroid cancer	0.000179	0.000451	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDK1—thyroid cancer	0.000177	0.000446	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HIF1A—thyroid cancer	0.000174	0.000439	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRAS—thyroid cancer	0.000168	0.000425	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRAS—thyroid cancer	0.000161	0.000408	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRAS—thyroid cancer	0.000161	0.000407	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—thyroid cancer	0.000145	0.000366	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—BRAF—thyroid cancer	0.000144	0.000364	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HPGD—thyroid cancer	0.000144	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRG1—thyroid cancer	0.000142	0.000358	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—thyroid cancer	0.000139	0.000351	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—thyroid cancer	0.000138	0.00035	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—thyroid cancer	0.000131	0.000331	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—thyroid cancer	0.000127	0.000322	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—thyroid cancer	0.000126	0.000319	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—thyroid cancer	0.000123	0.000311	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIF1A—thyroid cancer	0.000122	0.000308	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—thyroid cancer	0.000118	0.000299	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—thyroid cancer	0.000118	0.000297	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—thyroid cancer	0.000116	0.000294	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRAS—thyroid cancer	0.000113	0.000285	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—thyroid cancer	0.00011	0.000278	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—thyroid cancer	0.000109	0.000275	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—thyroid cancer	0.000104	0.000264	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—thyroid cancer	0.000104	0.000263	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—thyroid cancer	0.000101	0.000256	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BRAF—thyroid cancer	0.000101	0.000255	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRAS—thyroid cancer	9.8e-05	0.000248	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—thyroid cancer	9.69e-05	0.000245	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRAS—thyroid cancer	9.04e-05	0.000229	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—thyroid cancer	8.61e-05	0.000218	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—thyroid cancer	8.43e-05	0.000213	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TPR—thyroid cancer	8.26e-05	0.000209	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—thyroid cancer	8.24e-05	0.000208	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	8.13e-05	0.000206	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—thyroid cancer	7.78e-05	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—thyroid cancer	7.35e-05	0.000186	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—thyroid cancer	7.27e-05	0.000184	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—thyroid cancer	7.17e-05	0.000181	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—thyroid cancer	7.1e-05	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—thyroid cancer	6.62e-05	0.000167	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRAS—thyroid cancer	6.33e-05	0.00016	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—thyroid cancer	6.33e-05	0.00016	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC5A5—thyroid cancer	6.19e-05	0.000156	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—thyroid cancer	5.84e-05	0.000148	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—thyroid cancer	5.45e-05	0.000138	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—RXRA—thyroid cancer	5.2e-05	0.000131	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—thyroid cancer	4.84e-05	0.000122	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—thyroid cancer	4.63e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—thyroid cancer	4.09e-05	0.000103	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—thyroid cancer	3.28e-05	8.3e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.58e-05	6.53e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—thyroid cancer	2.25e-05	5.69e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—thyroid cancer	1.3e-05	3.28e-05	CbGpPWpGaD
